TW200427410A - Processed fat compositions for preventing and improving lifestyle-related diseases - Google Patents
Processed fat compositions for preventing and improving lifestyle-related diseases Download PDFInfo
- Publication number
- TW200427410A TW200427410A TW093101588A TW93101588A TW200427410A TW 200427410 A TW200427410 A TW 200427410A TW 093101588 A TW093101588 A TW 093101588A TW 93101588 A TW93101588 A TW 93101588A TW 200427410 A TW200427410 A TW 200427410A
- Authority
- TW
- Taiwan
- Prior art keywords
- glycyrrhizin
- fat
- crude
- group
- oil
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 201000010099 disease Diseases 0.000 title claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 55
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 26
- 238000012545 processing Methods 0.000 claims abstract description 25
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 14
- 150000004667 medium chain fatty acids Chemical class 0.000 claims abstract description 11
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 11
- 125000005456 glyceride group Chemical group 0.000 claims abstract description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 133
- 239000004378 Glycyrrhizin Substances 0.000 claims description 131
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 131
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 131
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 131
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 131
- 239000003925 fat Substances 0.000 claims description 57
- 239000003921 oil Substances 0.000 claims description 41
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 25
- -1 glycerin fatty acid ester Chemical class 0.000 claims description 20
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 19
- 239000000194 fatty acid Substances 0.000 claims description 19
- 229930195729 fatty acid Natural products 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- 241000202807 Glycyrrhiza Species 0.000 claims description 16
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 15
- 235000011187 glycerol Nutrition 0.000 claims description 15
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 14
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 14
- 229940010454 licorice Drugs 0.000 claims description 14
- 210000001596 intra-abdominal fat Anatomy 0.000 claims description 11
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 claims description 8
- 240000008917 Glycyrrhiza uralensis Species 0.000 claims description 8
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 6
- 235000014593 oils and fats Nutrition 0.000 claims description 6
- 238000006356 dehydrogenation reaction Methods 0.000 claims description 5
- 206010020880 Hypertrophy Diseases 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 201000001421 hyperglycemia Diseases 0.000 claims description 3
- 235000005911 diet Nutrition 0.000 claims description 2
- 230000000378 dietary effect Effects 0.000 claims description 2
- 208000027796 Blood pressure disease Diseases 0.000 claims 1
- 244000025254 Cannabis sativa Species 0.000 claims 1
- 239000004519 grease Substances 0.000 claims 1
- 230000002650 habitual effect Effects 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 21
- 239000003814 drug Substances 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 10
- 239000002537 cosmetic Substances 0.000 abstract description 8
- 235000013402 health food Nutrition 0.000 abstract description 8
- 230000036541 health Effects 0.000 abstract description 7
- FWWGXZYUURXJLK-UHFFFAOYSA-N glycyrin Chemical compound C=1C=2C(OC)=C(CC=C(C)C)C(OC)=CC=2OC(=O)C=1C1=CC=C(O)C=C1O FWWGXZYUURXJLK-UHFFFAOYSA-N 0.000 abstract description 6
- 206010020772 Hypertension Diseases 0.000 abstract description 5
- NZYSZZDSYIBYLC-UHFFFAOYSA-N glycycoumarin Chemical compound C=1C=2C(OC)=C(CC=C(C)C)C(O)=CC=2OC(=O)C=1C1=CC=C(O)C=C1O NZYSZZDSYIBYLC-UHFFFAOYSA-N 0.000 abstract description 3
- NPQWZAAWZLVQIZ-UHFFFAOYSA-N glycycoumarin Natural products COc1cc2OC(=O)C(=Cc2c(O)c1CC=C(C)C)c3ccc(O)cc3O NPQWZAAWZLVQIZ-UHFFFAOYSA-N 0.000 abstract description 3
- 208000008589 Obesity Diseases 0.000 abstract description 2
- 235000020824 obesity Nutrition 0.000 abstract description 2
- QHJJASRUTXHRAL-UHFFFAOYSA-N 4-[5,7-dimethoxy-6-(3-methylbut-2-enyl)-2h-chromen-3-yl]benzene-1,3-diol Chemical compound C=1C=2C(OC)=C(CC=C(C)C)C(OC)=CC=2OCC=1C1=CC=C(O)C=C1O QHJJASRUTXHRAL-UHFFFAOYSA-N 0.000 abstract 4
- UACNRZUVCUEUPY-UHFFFAOYSA-N 4-[7-hydroxy-5-methoxy-6-(3-methylbut-2-enyl)-2h-chromen-3-yl]benzene-1,3-diol Chemical compound C=1C=2C(OC)=C(CC=C(C)C)C(O)=CC=2OCC=1C1=CC=C(O)C=C1O UACNRZUVCUEUPY-UHFFFAOYSA-N 0.000 abstract 2
- FZKIFWZDWHZTMM-UHFFFAOYSA-N Dehydroglyasperin C Natural products COc1c(CC=C(C)C)c(O)cc2OCC(=Cc12)c3cc(O)cc(O)c3 FZKIFWZDWHZTMM-UHFFFAOYSA-N 0.000 abstract 2
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 235000015097 nutrients Nutrition 0.000 abstract 1
- 235000019197 fats Nutrition 0.000 description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 30
- 235000019198 oils Nutrition 0.000 description 27
- 239000000284 extract Substances 0.000 description 13
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- 235000013376 functional food Nutrition 0.000 description 9
- 230000002209 hydrophobic effect Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 229930003935 flavonoid Natural products 0.000 description 7
- 235000017173 flavonoids Nutrition 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 235000014121 butter Nutrition 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 235000012149 noodles Nutrition 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 239000003549 soybean oil Substances 0.000 description 4
- 235000012424 soybean oil Nutrition 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 210000000579 abdominal fat Anatomy 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000015243 ice cream Nutrition 0.000 description 3
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 235000010746 mayonnaise Nutrition 0.000 description 3
- 239000008268 mayonnaise Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 235000021419 vinegar Nutrition 0.000 description 3
- 239000000052 vinegar Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 229960000956 coumarin Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 235000011850 desserts Nutrition 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003760 tallow Substances 0.000 description 2
- 238000005809 transesterification reaction Methods 0.000 description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical group C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- XRCRJFOGPCJKPF-UHFFFAOYSA-N 2-butylbenzene-1,4-diol Chemical compound CCCCC1=CC(O)=CC=C1O XRCRJFOGPCJKPF-UHFFFAOYSA-N 0.000 description 1
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 description 1
- CNNBJLXLTIKXGJ-UHFFFAOYSA-N 3-phenyl-2h-chromene Chemical compound C1OC2=CC=CC=C2C=C1C1=CC=CC=C1 CNNBJLXLTIKXGJ-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Natural products CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 241001317416 Lius Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100034068 Monocarboxylate transporter 1 Human genes 0.000 description 1
- 102100025275 Monocarboxylate transporter 3 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 108091006607 SLC16A8 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000005523 excessive nutrition Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 108010025899 gelatin film Proteins 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 235000021070 high sugar diet Nutrition 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000018192 pine bark supplement Nutrition 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- LVTJOONKWUXEFR-UEZXSUPNSA-N protodioscin Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@@H]5O[C@]([C@H]([C@@H]5[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1)C)(O)CC[C@@H](C)CO[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O LVTJOONKWUXEFR-UEZXSUPNSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 229940106796 pycnogenol Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- QDQWGYLCDZBAMD-UHFFFAOYSA-N saponin C Natural products CC1C2C3CCC4C5(C)CCC(O)C(C)(COC6OC(CO)C(O)C(O)C6O)C5CCC4(C)C3(C)CCC27C8OC8C1(C)OC7=O QDQWGYLCDZBAMD-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000007864 suspending Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
- 150000003548 thiazolidines Chemical class 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Pyrane Compounds (AREA)
- Fats And Perfumes (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Edible Oils And Fats (AREA)
Description
200427410 玖、發明說明: 【發明所屬之技術領域】 t本發明係關於—種生活習慣病之預防及/或改善用之油 力、、且口物,其可使用於健康食品及保健機能食品(特定 保健食品、營養機能食品)等飲食品、醫藥品、醫藥部外品、 化妝品等。 【先前技術】 、源於營養過多及運動不足等生活習慣惡化之生活習慣病 逐已局較大社會問題。此處作爲生活習慣病可間舉内臟 月曰肪型肥滿、第二型糖尿病、高血脂症、高血壓症等,係 勢必惡化為動脈硬化症之多重危險因素徵候群。於是期望 持有預防及/或改善該等生活習慣病效果之組合物,且期望 該組合物形態為可以日常攝取之健康食品及保健機能食品 (特定保健食品、營養機能食品)等飲食品、醫藥品、醫藥部 外品、化妝品等。 夕重危險因素症候群,被認爲與Reaveni χ症狀⑴ 37,1595〜1607,1988); Kaplan之死亡四重奏(Archives 〇f Internal Medicine,149, 1514〜1520, 1989) ; DeFronz〇之胰島 素阻抗性症候群(Diabetes Care,14,173〜194,1991);松澤 之内臟脂肪症候群(Diabetes/Metabolism Reviews,i3, 3〜13, 1997)為相同病理概念,被認爲該等症候群共通原因因子係 胰島素阻抗性。 近年,根據過氧化體增殖劑應答性受體y(per〇xis〇me prolifemor-activated receptor γ: PPAR γ)之配體曲格列酮、 90211 200427410 匹格列酮、羅格列酮等噻唑烷衍生體研究,查明該等藥劑 對於第一型糖尿病患者改善胰島素阻抗性,表現血糖降低 作用,作爲胰島素阻抗性改善藥第二型糖尿病治療藥臨床 應用。再者,還查明該等噻唑烷衍生體表現增加皮下脂肪 而降低内臟脂肪,降低血中游離脂肪酸作用,降低企壓作 用,抗炎症作用等(Martens,F· M,et al,Drugs,62, 1463〜1480, 2002)。即,持有ΡΡΑΚγ配體活性之化合物可 改善胰島素阻抗性,對預防及/或改善内臟脂肪型肥滿、第 二型糖尿病、高血脂症、高血糖症等生活f慣病有效。 甘草係丑科甘草屬(Glycyrrhiza屬)植物,作爲食用或者醫 樂用(生藥)利用,作爲主要品種可以例舉光果甘草 (C^Cyrrhiza glabra)、G.烏拉爾甘草(G则^仏)、g脹果 甘草(G.inflata)等。每個品種均含有係親水性成分之甘草甜 素(甘草酸),而疏水性成分之類黃素母_根據品種含有特里 化合物。肖品種特異類黃素母嗣還可以利用力甘草品種鑑 定。 甘草中所獲得提取物中,多含有甘草類黃素母酮,甘草 甜素含1為極微量之甘草疏水性提取物,被認爲對多重危 險因子症候群之預防及/或改#有用(wo G2/47699)。再者, 最新研究表明,甘草疏水性提取物持有ΡΡΑΚγ配體活性, 其活性成分為類黃素母酮’特別為異戊二稀基類黃素母酮 (W〇〇3/〇373 16)。還表明,其中G·脹果甘草由來提取物之 ΡΡΑΙΙγ配體活性較高’係其提取物所含有異戍二稀基類普 素母剩之甘¥香豆素、甘草寧、職粗元甘草素C及脫氫粗 90211 200427410 凡甘草素D為持有高活性之成分(WO 03/037316)。並且,脫 虱粗元甘草素D係WO 03/037316中所發現新穎化合物。 另一方面,甘草疏水性類黃素母酮有基本上不溶解於 =,且有機溶劑提取物原樣容易固結,著色進行亦快等經 時變化顯著之性質,利用困難。為解決其問題,將甘草疏 水f生類頁素母酮溶解於中鏈脂肪酸三酸甘油酯中,將其甘 “水性類黃素相製劑作爲防酸化劑、抗菌劑、酵素阻 害劑、著色料、抗腫瘍劑、抗過敏劑、抗病毒劑等利用(專 利2794433)。而,專利2794433中並不限定化合物,且作爲 生活習慣病之預防及/或改善劑之利用並不廣爲人知。… 【發明内容】 蓉於上述説明,甘草香豆素、甘草寧、脫氫粗元甘草素c 及脫氫粗元甘草素D持有PPAR—體活性,對改善騰島素阻 抗性’預防及/或改善内臟脂肪型肥滿、第二型糖尿病、高 血脂症、高血壓症等生活習慣病有效。而,由於該化合物 水溶解性及安定性欠佳’有難利用於飲食品及醫藥品等之 缺點。所以,本發明以提供—種生活f慣病之預防及/或改 善用之組合物為課題,其含有由甘草香豆素、甘草寧、脫 氫粗元甘草素C及脫氫粗元甘草素〇所組成群組中選擇至 少-種化合物,可以利用於健康食品及保健機能食品(特定 保健食品、營養機能食品)等飲食品、醫藥品、醫藥部外品、 化妝品等。 +本發明者等,鑒於上述實情進行銳意研究之結果,將甘 早香m草寧 '脫氫粗元甘草素c及脫氫粗元甘草素d 90211 200427410 解於—種油脂’藉由溶解於該油脂提高該等化合物 文:性’且提高製作成飲食品、醫藥品、醫藥部外品、化 妝品等加工性,完成了本發明。 即,本發明係關於一種生活習慣病之預防及/或改善用油 脂加工組合物並胰島素阻抗性改善㈣腊加卫組合物,立 =徵在於含有溶解有由甘草香豆素、甘草寧、脫氫粗元甘 早素c及脫氫粗元甘草素D所組成群組中選擇至少一種化 合物。 且,本發明係關於預防及/或改善生活習慣病方法,改善 騰島素阻抗性之方法,㈣及/或改善高血_之方法,並且 減少腹腔内脂肪之方法,其使用含有溶解有由甘草香豆 素、甘草寧、脫氫粗元甘草素C及脫氫粗元甘草素〇所組成 群組中選擇至少一種化合物之油脂之組合物。 以下’詳細説明本發明實施形態。 一本I明之生活習慣病之預防及/或改善用之油脂加工組 δ物,其特徵在於含有溶解有由甘草香豆素、甘草寧、脫 氫粗元甘草素C及脫氫粗元甘草素D所組成群組中選擇至 少一種化合物之油脂。 且’本發明之胰島素阻抗性改善用油脂加工組合物,其 4寸欲在於含有溶解有由甘草:香豆素、甘草寧、脫氫粗元甘 草素C及脫氫粗元甘草素d所組成群組中選擇至少一種化 合物之油脂。 本發明之油脂加工組合物,希望在該化合物中,含有脫 氫粗元甘草章D,並且含有由甘草香豆素、甘草寧及脫氫粗 90211 -9- 200427410 元甘草素C所組成群組中選擇至少一種化合物。再者,更好 為含有脫氫粗元甘草素c及脫氫粗元甘草素D,並含有甘草 香丑素或甘草寧中任意一種。特別為,最好是含有甘草香 丑素、甘草寧、脫氫粗元甘草素C及脫氫粗元甘草素D全部。 該化合物,因與甘草香豆素及甘草寧㈣㈣衍生物同 樣,持有ΡΡΑΙΙγ配體活性,較善胰島素阻抗性,以及預 防及/或改善内臟月旨肪型肥滿、第二型糖尿病、高血脂症、 南血壓症等生活習慣病有效。 本發明所使用甘草香豆素(glycycoumarin)及甘草寧 (glycyrin),係分類為3-芳香基香 黃素母酮,為下述一般式(1)所表 豆素(3-arylcoumarin)之類 示化合物。
[式中,R=H之情形為甘草香 旦素,R=CH3之情形為甘草寧。 本發明所使用脫氫粗元甘曾主^ 、 皁素C及脫氫粗元甘草素D,名 分痛為isoflav-3-ene之類普去瓜立 ”素母_,為下述一般式(2)所表六 化合物。 90211
-1(K 200427410
[式中,R=H之情形為脫氫粗元甘草素c,R=CH3之情形為脫 氫粗元甘草素D。] 甘草香五素、甘草寧、脫氫粗元甘草素c及脫氫粗元甘草 素D係甘草中烏拉爾甘草(Glycyrrhiza uralensis)中特異含 有之成分,其他品種基本上不含有。而,G.烏拉爾甘草與 其他品種之雜種中有時含有。該化合物,可以通過使用 ODS(矽膠擔體上化學結合有十八烷基硅烷鍵之充填劑)等 逆相管柱之高效液相層析儀(HpLC)分析,與其他類黃素母 酮分離,檢出並定量。 本發明中獲得甘草香豆素、甘草寧、脫氫粗元甘草素C 及脫氯粗元甘草素D方法並不特別限定,可以從α烏拉爾甘 =種甘频得。從乾草獲得該化合物之情形,其方法並不 4寸別:定’可以例舉使用乙醇、乙酸乙酯、丙酮等有機溶 劑之^取等。由上述提取所獲得甘草疏水性提取物中含有 ^ 物可以直接以提取物形態使用,也可以藉由管柱 處理、脫臭處理、脫色處理等粗精製或精製之物。去秋, 該化合物,本發明中可以使用其他植物等天 二勿 化學合成之物,或者藉由培養細胞等生合成之物中任^ 90211 200427410 種。亚且,該化合物可以使用精製之物,且不含有作爲飲 艮口口、%藥品、醫藥部外品、化妝品等不適當雜質之情況 下可以使用粗精製之物。 乍爲本务月所使用油脂可以例舉甘油脂肪酸醋。作爲甘 油脂肪酸酯,可以為包含中鏈脂肪酸三酸甘油酯之甘油脂 肪H曰,及/或包含部分甘油酯之甘油脂肪酸酯。該情形, 中鏈脂肪酸三酸甘油酯、部分甘油酯之任意一種佔全體甘 油脂肪酸酯之50重量%以上為好,佔7〇重量%以上更好。 且,可以使用含有50重量〇/〇中鏈脂肪酸三酸甘油酯,5〇重 量%甘油酯之甘油脂肪酸酯。 其中,中鏈脂肪酸三酸甘油酯係,將碳素原子數為6〜12 之脂肪酸作爲構成脂肪酸之物。其脂肪酸構成比率並不特 另J限疋,希望;%i素原子數為8〜1〇之脂肪酸構成比率在%重 里/〇以上,更好為70重量%以上。特別希望2〇。〇條件下比重 為0.94〜0.96,2(TC條件下黏度為23〜28 cp之中鏈脂肪酸三 酸甘油酯。且,中鏈脂肪酸三酸甘油酯,可以使用天然由 來物及藉由酯交換等調製之物等任意一種。 其中部分甘油酯,係二酸甘油酯(丨》雙醯甘油、i,3_雙醯 甘油)或一酸甘油酯(1-單醯甘油、孓單醯甘油)。作爲部分 甘油酯,可以使用任意一種,,也可以使用兩者混合之物, 但從加工性觀點上希望為雙醯甘油。且,部分甘油酯,可 以使用天然由來物及藉由酯交換等調製之物等任意一種。 再者,作爲部分甘油酯,希望構成脂肪酸碳素原子數為 6〜24 〇 90211 -12- 200427410 可以使用中鏈脂肪 再者,本發明中所使用冑分甘㈣ 酉文之部分甘油酯。 =明中’將甘草香豆素、甘草寧、脫氯粗元甘草素C 甘草素D溶解於油脂之方法,並不特別限定,可 二:吊用撹拌、混合等操作實施。使用含有該化合物之
物以外’ ί該化合物之粗精製品之情形,由於含有該化合 /雜貝’希望通過授拌、混合等操作將該化合物溶解 =脂後,通過料、離心分離轉作除以料油脂之 雜貝。使用該化合物粗精製品之情形,容易獲得均一溶液。 :,使用含有該化合物之提取物或該化合物之粗精製品之 情形’也可錢用預先溶解於乙料有機溶劑,將該溶液 與油脂混合後除去有機溶劑之方法。 —通4吊’甘草香丑素、甘草寧、脫氫粗元甘草素α脫氯粗 元甘草素D呈粉末狀態時在啊以上不安乙醇等有機溶 J中’合液狀悲日寸在25 C以上不安定。@,將該化合物溶解 於本發明所使用油脂之狀態下在25Χ:以上也安定。 一本發明之生活習慣病之預防及/或改善用之油脂加工組 合物,在生活習慣病中適用於由内臟脂肪肥滿、第二型糖 尿病、同血脂症及咼血壓症所組成群組中選擇至少一種疾 患,特別適用於内臟脂肪肥滿及/或第二型糖尿病。更具體 -占,適用於咼血糖之預防及/或改善、腹腔内脂肪減少。 本發明之生活習慣病之預防及/或改善用之油脂加工組 合物’及胰島素阻抗性改善用之油脂加工組合物,並不限 定其形態,可以利用於健康食品及保健機能食品(特定保健 90211 -13- 200427410 食品、營養機能食品)等飲食品、醫藥品、醫藥部外 ,品等。例如’可以將溶解有由甘草香豆素、甘草寧、脫 虱粗几甘草素C及脫氫粗元甘草素D所組成群組中選擇至 少-種化合物之油脂原樣單獨作爲烹調用、軟膠囊劑用、 化裝水用等利用。a ’由於可以與油性對象物自由混合, 可乂根據目的與其它油脂混合調整物理性質。該情形,豆 他油月曰希望為食用或醫藥用,其種類及使用量可以根據考 慮製品所要求各個物理性質及使用溫度域等諸條件決定, y以根據調整其種類及使用量調節稠度及溶點等特i生。作 爲其他油脂,例如可以使用玉米油、菜籽油、高三芬子酸 甘油醋菜籽油、大豆油、撖欖油、紅花油、綿實油、葵花 油、米糠油、棕櫚油、棕櫚核油等植物油;魚油、牛脂、 豬脂、乳脂1黃油等動物油;將該等作爲原料進行分類、 添水、酯交換等之油脂;該等之混合油等。 如上所獲得本發明之油脂加工組合物,可以作爲色拉油 及油炸油等液狀油脂;麥淇淋或黃油等可塑性油脂利用, 可以利用於油中水型乳膠、水中油型乳膠等。且,作爲將 該等作爲原材料製造之飲食用之油脂加工組合物,例如有 口香糖、巧克力、糖果、果子凍、餅乾、鹹餅乾等點心類; 冰淇淋、冰點等冷凍點心類;乳飲料、清涼飲料、營養飲 料、美容飲料等飲料;切麵、中華麵、意大利麵、即食麵 等麵類;蒲鋅、竹輪、半片冑魚糜製品;濃調味汁、蛋黃 醬、調味汁等調味料;麵包、火腿、湯、各種小袋包裝食 口口、各種冷參食品等,也可以利用於寵物食品及家畜飼料 90211 -14- 200427410
再者,作爲強化營養之目的,可以^ D . ^ J以添加、併用維生素A、 七寻各種維生素類;作爲呈味劑 麵々 木^了以添加、併用各種鹽 大、、各種香料、乳關聯物質,例 發 ^ U如王月曰奶粉、脫脂奶粉、 酵礼、乳脂肪等。且,作爲上 忭局上述以外原材料,使用於一 版油中水型麥淇淋、水中油型麥 劑等全部可以使用。“μ寻之防氧化劑、著色 人本發明之生活習慣病之預防及/或改善用之油脂加工組 一&物’及胰島素阻抗性之改善用油脂加工組合物中甘草香 :素、甘草寧、脫氫粗元甘草素C及脫氫粗元甘草素D含 罝,為發揮該化合物之生活習慣病之預防及/或改善效果, 2爲該化合物之總量,可以為油脂加工組合物中含有成人 母人母日可攝取之量0.01〜1〇〇 mg/kg體重,更好為〇 1〜⑺ mg/kg體重。 且,本發明之生活習慣病之預防及/或改善方法,胰島素 阻抗性之改善方法,高血糖之預防及/或改善方法,及減少 腹腔内脂肪之方法,其特徵在於使用含有溶解有由甘草香 豆素、甘草寧、脫氫粗元甘草素c及脫氫粗元甘草素d所組 成群組中選擇至少1種化合物之油脂之上述組合物。 【實施方式】 以下,舉例進一步具體説明本發明,而本發明並不局限 於該等實施例。 (實施例1) 攸西北產甘早(G·烏拉爾甘草)3 〇〇 kg進行乙醇提取(浸於 90211 -15- 200427410 1840 L乙醇中,35〜45°C,遮光條件下重複進行提取2小時 之操作2次)、合併所獲得提取液,藉由濃縮、晶析、滤別、 乾燥、粉碎獲得13.46 kg甘草疏水性提取物。 將上述甘草疏水性提取物20 g與中鏈脂肪酸三酸甘油醋 (MCT)Act〇r M-2(理研維生素株式會社:脂肪酸組成為 C8:C10 = 99:1)180 g混合,在大約60°C保溫攪拌大約H固小 時。其後,藉由離心分離除去不溶成分,將油層作爲MCT 溶液(189.4 g)獲得。 所獲得MCT溶液使用HPLC用甲醇稀釋1〇〇倍,以下述條 件進行HPLC分析結果,MCT溶液每1 g中甘草香豆素、甘 草寧、脫氫粗元甘草素c及脫氫粗元甘草素D各含有2〇 mg、1·4 mg、6.8 mg、5.5 mg 〇 HPLC分析條件 分析管柱使用 J,sphere ODS-H80, 4.6x250 mm(YMC社 製)’管柱溫度為40°C。作爲移動相,對於1〇 酸水溶 液在分析開始至15分鐘爲止將乙腈比率—定為35%,i5分 鐘以後一定比率提高使65分鐘後達到7〇%,從“分鐘後至 70分鐘爲止一定為70%之梯度條件下流速為i爪丨/分。注入 量為20 μ卜檢出波長為350 nm。保持時間為甘草香豆素為 分,脫氫粗元甘草素W8Q分,甘草寧為49.2分了脫 氫粗元甘草素D為56·5分。 旦上述MCT溶液分別在代、饥、啊保存4週,每週定 量甘草曰香豆素、甘草寧、脫氫粗元甘草素〇及脫氫粗元甘草 素D含量。以保存開始時各含量為刚%,保存安定性表示 90211 -16- 200427410 為保存後/保存開始時含量之比率。 4 C保存結果表示於表丨,2 保存結果表示於表3。、,,^ 果表不於表2, 4( 一 、 亚表中所表示化合物1為甘莖未 豆素,化合物2為甘草寧,化人物 為甘早曰 丁化口物3為脫氣粗元甘草辛Γ 合物4為脫氫粗元甘草素D。 '、 (比較例1) ”將實施m中所使用甘草疏水性提取物代替Α“。…溶 解於乙醇獲得⑽mg/ml乙醇溶液。該乙醇溶液使用HPLC 用甲醇稀釋1G0倍’進行hPLC分析結果,乙醇溶液每】ml 中甘草香丑素、甘草寧、脫氫粗元甘草素c及脫氫粗元甘草 素0各含有 2.4 mg、1.6 mg、7.4 mg、5.8 mg。 使用該乙醇溶液與實施例丨同樣進行保存安定性試驗。其 結果表示於表1〜3。 41C贿 保存安定性 化合物1 Λ合物2 化合物3 MCT溶被 関姶時 100% 100% 1 00% 化合_4 10 0% 1週後 2: 1 9 9¾ B7% 9 9% 9 9% 9 7% 9 9% 98% 9 7% 9 8% 9 8% 9 7% 99% 4邏後 開始時 9 7% 10 0% 9 7% 1 0 0% 97% 10 0% 9 7% 10 0¾ 乙 1週後 ϋΐΐ 3週後 後 8 7% Β%% 89% §3% %7% 8 6 % 88% 9 2% 8 8% 85% 8 6% 9 1% 8 7¾ β 6% 8 8% 9 3% 90211.doc -17- 200427410
表Z MCT壤 i澄彼 5$辦 贿安定性 化合物I 化合物2 化合物3 化働4 _関始時 100¾ 10 0¾ ! !〇〇% 1 0 0% —後“ 98% 9 B% I 9 8% 9 8% 屋 9 7% 9 7¾ 9 5% 9 7% 一 3週後 I 9 6^ 97% 9 6¾ 96% :_ 4週德 ’…丨"丨丨· 97¾ 98¾ 9㈣ 98% L圈始晦 1 0 0¾ 10 0¾ 10 0% 100% 1適後 89¾ 8 9 % 8 4% 8 9% .週織 90¾ 8 9¾ 7 6薅 8 8¾ I 3週龜 8 8% 8 7% 6 8% 8 6 % \ _ 4適総 8 8% 8 7% 3 8 % 8 0% 表3 4❹雜存 開始時 保雜定性
Mci液、 乙醇溶液 後 ά^μ __時後 麗 3遍後 後 適 化綠1 10 0% 95¾ 95% 97% 9?駕 10 0% 88% 92% B2 36 ¾ 化合物2 10 0¾ 化合物I 1 0 0 % I匕合輸4 1 0 0 % 96% 9 5% 9 8% 9 9% I Q0% B?% 9 3% 90% % 9 5% ^2% 93¾ BI% 10 0% 6 6% 4 1% 2 4% % 9 5 % 9 4 % 9 S% 9 5 % 1 0 0 % 8696
8 ti U ^ % 在C保存下,化合物1〜4均在MCT溶液與乙醇溶液中安 疋在25 C保存下,與化合物1〜4均在MCT溶液安定相比, 乙醇溶液中特別為化合物3不安^。在赋保存下,與化合 物1〜4均在衫相比,乙料液巾制為化合 90211 -18 - 200427410 及4不安定。 該等結果表示,在乙醇溶液中化合物3及4在25〜40°C下保 存不安定,而MCT溶液中與保存溫度無關化合物1〜4均安 定。 (實施例2)糖尿病預防作用 將第二型糖尿病模型動物KK-Ay小鼠(雌,6週齡)分爲3 群(各群5只)作爲A群、B群、C群,各自由攝取表4所示飼料 4週。並且,基本飼料使用組成爲酪蛋白20重量%,玉米澱 粉49.948重量%,蔗糖10重量%,纖維素粉5重量%,AIN-93 混合礦物質3.5重量%,AIN-93混合維生素1重量%,重酒石 酸膽鹼〇_25重量%,第三丁氫醌0.002重量%及1^胱胺酸0.3 重量%(合計90重量%)之粉末精製飼料(AIN-93G改變, Oriental酵母株式會社),且MCT使用Actor M-2(理研維生素 株式會社)。 給餌期間中每週從小鼠尾靜脈少量採血,使用簡易式血 糖測定器GLUTEST ACE(株式會社三和化學研究所)測定血 糖值。將其結果表示於表5。 表4 A群 B群 C群 基本飼料 90份重量 90份重量 90份重量 大豆油 10份重量 8份重量 8份重量 MCT 一 3份重量 2份重量 實施例1之 MCT溶液 — — 1份重量 計 100份重量 101份重量 101份重量 90211 -19- 200427410 fmt 潰5 血糖値《義> :1 A鮮 B群 C群 開始時 m± 4 !4?± 8 1§3± ? 1邏 後 302 ±33 217±60 115±29 2週 後 36? 土 22 376±16 261 ±43 3週後 438 ±26 411 ±16 2?0±26 * 4週後 m±n 431 ±19 292±43 * 平均±標_誤差¢11=¾ ·《ρφ·〇5) Α群中,小鼠血糖值經時上升,觀察到糖尿病發症。Β群 中,與Α群相同小鼠血糖值上升觀察到糖尿病發症,觀察不 到MCT之影響。另一方面,C群中,與A群及B群相比較小 鼠之血糖值上升明顯被抑制,觀察到來源於實施例1之MCT 溶液之糖尿病預防作用。 該等結果表示,含有甘草香豆素、甘草寧、脫氫粗元甘 草素C及脫氫粗元甘草素D之MCT溶液對糖尿病預防有效。 (實施例3)内臟脂肪減低作用 將C57BL/6J小鼠(雌,8週齡)自由攝取高脂肪·高糖分食8 週,達到食餌性肥滿狀態。並高脂肪·高糖分食使用組成為 酪蛋白25重量%,玉米澱粉14.869重量%,蔗糖20重量%, 大豆油2重量°/〇,豬油14重量%,牛脂14重量%,纖維素粉5 重量%,AIN-93混合礦物質3.5重量%,AIN-93混合維生素1 重量%,重酒石酸膽鹼0.25重量。/〇,第三丁氫醌0,006重量 %,L-胱胺酸0.375重量%之半固形化精製飼料(Oriental酵母 株式會社)。
其後,將小鼠分爲3群(各群5只)作為A群、B群、C群。A 90211 -20- 200427410 群為CE-2飼料(曰本CLEA株式會社),B群為添加有MCT 3 重量%之CE-2飼料,C群為添加有實施例1之MCT溶液3重量 %之CE-2飼料,各自由攝取4週。並且作爲MCT使用Actor M-2(理研維生素株式會社)。絕食一晚之小鼠在乙醚麻醉下 開腹,從腹大動脈採血屠殺後,摘出腸間膜脂肪、腎臟周 邊脂肪、子宮周邊脂肪,測定重量。並將腸間膜脂肪重量、 腎臟周邊脂肪重量、子宮周邊脂肪重量之和作爲腹腔内脂 肪重量。將其結果表示於表6。 表6 A群 Β群 C群 攝餌量 (g/日/匹)丨 土 ius L89±0,27 2.S3±0.28 體重⑻ 22H2 22/8±0.6 22.0±0· 4 脂肪重量(g) •腸間膜脂肪 •腎臟周邊脂肪丨 *子宫周邊脂肪 •腹腔内脂肪 0>160±0.0Π (US9 土^⑽9 0,3041:0.010 022 土 0*02δ 0*17δ±0-0!5 (U64i 0.035 (K2&9 土 0*063 0.628 ±0· M l (U25±0.G16 j 0,091 ±0.007 * 0.185±0,013 * 0.401 土0,033 孝 1 平均土標準誤差· ^ΚΟ.Οδ) 攝餌量及體重在Α群、Β群、C群中觀察不到差別。Β群中 與Α群相比在腸間膜脂肪重量、腎臟周邊脂肪重量、子宮周 邊脂肪重量及腹腔内脂肪重量上觀察不到差別,觀察不到 MCT之影響。另一方面,C群中,與A群及B群相比,腸間 膜脂肪重量雖然沒有有意差而明顯減少,腎臟周邊脂肪重 量、子宮周邊脂肪重量及腹腔内脂肪重量有意減少。即, 藉由攝取高脂肪高糖分食儲積之内臟脂肪,通過攝取含有 90211 -21 - 200427410 實施例1之MCT溶液之飼料減少。 該等結果表示,含有甘莖棄$ I ^ 有甘卓香且素、甘草寧、脫氫粗元甘 早素C及脫鼠粗儿甘卓素之1VT Γ1 T、、六V* 丄 之MCT/合液對内臟脂肪減少有 效。 (實施例4)軟膠囊劑之製造 將貫施例1之MCT溶液’使用轉子式軟膠囊製造裝置壓入 於明膠皮膜中,獲得到内容量為350 mg之軟膠囊劑。 (實施例5)麥淇淋之製造 在硬化綿實油(商品名:Sn0w Light,鐘淵化學工業株式 會社)80份重量,實施例1之撾(::丁溶液2〇份重量,無鹽黃油 (四葉乳業株式會社)1〇份重量中,添加脂肪酸單甘油酯(商 品名:Emarujy MS ,理研維生素株式會社)〇·2份重量,卵 磷脂0.2份重量,在60°C加熱溶解調製油相。 在所調製油相84.9份重量中邊攪拌邊添加151份重量 水’進行乳化20分鐘後’使用Comb in at or冷卻捏合獲得麥 淇淋。 (實施例6)濃縮乳之製造 將實施例1之MCT溶液10份重量在70°C加熱溶解後,依次 浴解印璃脂0 · 1份重量及甘油脂肪酸g旨〇 · 1份重量調製油相。 將脫脂奶粉25份重量,甘油脂肪酸酯〇·1份重量,嚴糖脂 肪酸酯0·1份重量溶解於60°C之水64.6份重量中調製水相。 將所調製水相與油相預備乳化後,使用超高溫瞬間(UHT) 殺菌機在145°C殺菌4秒。隨後真空冷卻後,使用均質化機 用10 MPa壓力均質化,進一步平板冷卻至l〇°c獲得加工濃 90211 -22- 200427410 縮乳。 (實施例7)製造蛋黃醬 將釀造醋10份重量,食鹽1份重量,砂糖〇·6份重量,芥 粉末0.2份重量,麩胺酸鈉〇·2份重量加入於混合器,在15〜2〇 C下擾掉混合调製水相。然後邊一點點添加米白絞油“份 重里,貝施例1之MCT溶液1 〇份重量中添加丨〇份重量卵黃, 攪拌礼化所獲得乳化液(1〇〜15。〇,在15〜20Τ:下攪拌,預 備乳化。隨後使用膠磨機進行完成乳化獲得蛋黃醬。 【產業上利用可能性】 根據本务明,可以獲得可利用於健康食品及保健機能食 ασ (特定保健食品、營養機能食品)等飲食品、醫藥品、醫藥 15外ππ、化妝品等之油脂加工組合物。本發明之油脂加工 、、且合物,對改善胰島素阻抗性以及預防及/或改善内臟脂肪 !肥滿、第二型糖尿病、高血脂症、高血壓症等生活 病有效。 、 90211 -23-
Claims (1)
- 拾、申請專利範園: 1. 一種油脂-加工組合物,其係用於生活習慣病之預防及/ 或改善,其特徵在於含有溶解有由甘草香豆素、甘草 寧、脫氫粗元甘草素C及脫氫粗元甘草素D所組成群組 中選擇至少一種化合物之油脂。 2· 一種油脂加工組合物,其係用於改善胰島素阻抗性,其 特徵在於含有溶解有由甘草香豆素、甘草寧、脫氳粗元 甘草素C及脫氫粗元甘草素d所組成群組中選擇至少一 種化合物之油脂。 3·如申請專利範圍第1或2項之油脂加工組合物,其特徵在 於含有由甘草香豆素、甘草寧、脫氫粗元甘草素c及脫 氳粗元甘草素D所組成群組中選擇至少一種化合物,作 爲其總量為成人每人每曰可攝取〇〇1〜1〇〇 mg/kg體重。 4·如申請專利範圍第丨至3項中任一項之油脂加工組合 物,其特徵在於油脂係含有中鏈脂肪酸三酸甘油酯及/ 或部分甘油酯之甘油脂肪酸酯。 5·如申請專利範圍第4項之油脂加工組合物,其特徵在於 油脂係含有50重量%以上中鏈脂肪酸三酸甘油酯之甘 油脂肪酸g旨。 6·如申請專利範圍第4項之油脂加工組合物,其油脂係含 有50重量%以上部分甘油酯之甘油脂肪酸酯。 7.如申請專利範圍第1項之油脂加工組合物,其中生活習 慣病係由内臟脂肪型肥滿、第二型糖尿病、高血脂症及 南血壓症所组成群組中選擇至少一種。 90211 200427410 士申月專利範圍苐1項之油脂力口工組合物,其中生活習 慣病係内揭脂肪型肥滿及/或第二型糖尿病。 9·如申請專利範圍第⑴項中任一項之油脂加工組合 物,其係飲食用。 10.如申請專利範圍第⑴項中任一項之油脂加工組合 物,其係醫藥用。 11·如申請專利範圍第mo項中任—項之油脂加工組合 物:其中由甘草香豆素、甘草寧、脫氫粗元甘草素C及 脫氫粗元甘草素D所組成群組中選擇至少一種化合物 係烏拉爾甘草(Glycyrrhiza uralensis)由來。 12·:種預防及/或改善生活習慣病之方法,其係使用含有 >谷解有由甘草香豆辛、廿曾办 _ ^ ’、 草f、脫風粗元甘草素C及脫 氫粗元甘草素D所組成群組中選擇至少一種化合物之 油脂之組合物。 A -種改善胰島素阻抗性之方法,其係使用含有溶解有由 甘早香豆素、甘草寧、脫氫粗元甘草素c及脫氫粗元甘 卓素〇所組成群組中選擇至少一種化合物之油脂Μ 合物。 、 14·-種預防及/或改善高血糖之方法,其係使用含有溶解 有由甘草香丑素、甘草寧、脫氫粗元甘草素α脫氫粗 '甘:素〇所組成群組中選擇至少—種化合物之油脂 之組合物。 15·-種減少腹腔内脂肪之方法,其係❹含有溶解有由甘 早香豆素、甘草寧、脫氫粗元甘草素C及脫氫粗元甘草_ 90211 -2 - 200427410 素D所組成群組中選擇至少一種化合物之油脂之組合 物0 一一 90211 200427410 柒、指定代表圖: (一) 本案指定代表圖為:(無) (二) 本代表圖之元件代表符號簡單說明: 捌、本案若有化學式時,請揭示最能顯示發明特徵的化學式: (無) 90211
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003016023 | 2003-01-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200427410A true TW200427410A (en) | 2004-12-16 |
Family
ID=32767458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW093101588A TW200427410A (en) | 2003-01-24 | 2004-01-20 | Processed fat compositions for preventing and improving lifestyle-related diseases |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2004064830A1 (zh) |
TW (1) | TW200427410A (zh) |
WO (1) | WO2004064830A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI406867B (zh) | 2005-09-30 | 2013-09-01 | Suntory Holdings Ltd | And a method for producing a high content of episesamin |
SG10201601998PA (en) | 2006-03-31 | 2016-04-28 | Suntory Holdings Ltd Jp | Compositions containing lignan-class compounds |
JP4910092B2 (ja) * | 2006-10-12 | 2012-04-04 | 富山県 | 植物が含有するフラボノイドの組成比率による品種識別法 |
CN110354119A (zh) * | 2018-03-26 | 2019-10-22 | 中国农业大学 | 甘草香豆素在制备预防和/或治疗药物性肝损伤的药物中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2794433B2 (ja) * | 1989-02-02 | 1998-09-03 | 丸善製薬株式会社 | 甘草疎水性フラボノイド製剤 |
TWI329516B (en) * | 2000-12-12 | 2010-09-01 | Kaneka Corp | Composition for preventing or ameliorating multiple risk factor syndromes and visceral fat-type obesity |
IL160964A0 (en) * | 2001-10-11 | 2004-08-31 | Kaneka Corp | Peroxisome proliferator activated receptor ligand and process for producing the same |
JP2003252784A (ja) * | 2002-02-27 | 2003-09-10 | Kanegafuchi Chem Ind Co Ltd | α−グルコシダーゼ阻害剤 |
JP4191420B2 (ja) * | 2002-03-26 | 2008-12-03 | 株式会社カネカ | 甘草疎水性抽出物を含有してなる食用油脂組成物 |
-
2004
- 2004-01-20 TW TW093101588A patent/TW200427410A/zh unknown
- 2004-01-23 WO PCT/JP2004/000599 patent/WO2004064830A1/ja active Application Filing
- 2004-01-23 JP JP2005508126A patent/JPWO2004064830A1/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JPWO2004064830A1 (ja) | 2006-05-18 |
WO2004064830A1 (ja) | 2004-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6745250B2 (ja) | モリンガエキス | |
TWI329516B (en) | Composition for preventing or ameliorating multiple risk factor syndromes and visceral fat-type obesity | |
JP4179494B2 (ja) | ペルオキシソーム増殖剤応答性受容体リガンド剤 | |
US20180104299A1 (en) | Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a satiation agent for the treatment of obesity | |
KR101912481B1 (ko) | 조성물, 및 당대사 개선제, 및 당대사 개선방법 | |
KR20110082052A (ko) | 농후유동식 | |
CN102665725A (zh) | 高血脂症改善剂、贫血改善组合物、尿酸值降低组合物以及饮料食品 | |
EP1481675A1 (en) | Body temperature elevating agents | |
JP6445686B2 (ja) | ジペノサイド75の抗糖尿病効果 | |
US20070098761A1 (en) | Processed fat composition for preventing/ameliorating lifestyle-related diseases | |
JP2009286703A (ja) | D−タガトースを有効成分とする体脂肪蓄積改善剤およびメタボリックシンドローム改善剤 | |
TW200427410A (en) | Processed fat compositions for preventing and improving lifestyle-related diseases | |
JP2015182987A (ja) | 抗炎症剤 | |
JP6167357B1 (ja) | 糖尿病の改善予防剤 | |
JP6912214B2 (ja) | 赤血球機能向上剤 | |
JPWO2004045632A1 (ja) | ペルオキシソーム増殖剤応答性受容体リガンド剤 | |
JP6095251B1 (ja) | 糖尿病の改善予防剤 | |
JP2009126790A (ja) | 血流改善剤およびそれを含有する飲食品 | |
JP2008088087A (ja) | 血糖値上昇抑制剤 | |
KR101753244B1 (ko) | 트리고넬린을 유효성분으로 포함하는 숙취 해소 및 간기능 개선용 조성물 | |
JP7220838B2 (ja) | 経口組成物 | |
JP4469407B1 (ja) | 血中中性脂肪低下剤 | |
JP4469406B1 (ja) | 血中コレステロール低下剤 | |
JP2007246471A (ja) | 血中中性脂肪上昇抑制剤およびその製造方法 | |
JP2015042630A (ja) | 運動併用時の早期血糖低下剤 |